"4"^^ . "209147" . . "RIV/00023001:_____/11:00002625!RIV12-MZ0-00023001" . "Treatment and prevention of chronic viral hepatitis"@en . . "Viry hepatitidy B a C pat\u0159\u00ED mezi tzv. hepatotropn\u00ED viry, predilek\u010Dn\u00EDm m\u00EDstem jejich replikace jsou j\u00E1tra a nejz\u00E1va\u017En\u011Bj\u0161\u00ED komplikac\u00ED chronick\u00E9 infekce t\u011Bmito viry je jatern\u00ED cirh\u00F3za. Oba viry se p\u0159en\u00E1\u0161\u00ED parenter\u00E1ln\u011B. Proti viru hepatitidy B je v sou\u010Dasn\u00E9 dob\u011B k dispozici vysoce \u00FA\u010Dinn\u00E1 a bezpe\u010Dn\u00E1 rekombinantn\u00ED vakc\u00EDna. Plo\u0161n\u00E9 o\u010Dkov\u00E1n\u00ED vedlo k v\u00FDrazn\u00E9mu sn\u00ED\u017Een\u00ED incidence nov\u00FDch p\u0159\u00EDpad\u016F HBV. U pacient\u016F, kte\u0159\u00ED trp\u00ED chronickou HBV infekc\u00ED, je nutno l\u00E9\u010Dbou zastavit replikaci viru. Prvn\u00ED mo\u017Enost\u00ED je dosa\u017Een\u00ED imunitn\u00ED kontroly replikace l\u00E9\u010Dbou peginterferonem alfa, druhou mo\u017Enost\u00ED je dlouhodob\u00E9 pod\u00E1v\u00E1n\u00ED syntetick\u00FDch antivirotik, prvn\u00ED volbou je dnes tenofovir nebo entekavir. Proti viru hepatitidy C nen\u00ED v sou\u010Dasn\u00E9 dob\u011B k dispozici \u00FA\u010Dinn\u00E1 vakcinace. P\u0159enosu infekce je nutno se br\u00E1nit dodr\u017Eov\u00E1n\u00EDm hygienick\u00FDch z\u00E1sad v rodin\u00E1ch i ve zdravotnick\u00FDch za\u0159\u00EDzen\u00EDch, vysoce d\u016Fle\u017Eit\u00E9 je prov\u00E1d\u011Bt screening v rizikov\u00FDch skupin\u00E1ch osob. Chronickou HCV infekci lze l\u00E9\u010Dbou eliminovat z organizmu, \u00FA\u010Dinn\u00E1 je pouze kombinace peginterferonu alfa s ribavirinem, eliminace viru se zat\u00EDm da\u0159\u00ED dos\u00E1hnout jen u \u010D\u00E1sti l\u00E9\u010Den\u00FDch pacient\u016F." . "L\u00E9\u010Dba a prevence chronick\u00FDch virov\u00FDch hepatitid" . "RIV/00023001:_____/11:00002625" . "CZ - \u010Cesk\u00E1 republika" . . "1802-3150" . . . "5" . . . . . "[6C60ABDC51C1]" . "Viry hepatitidy B a C pat\u0159\u00ED mezi tzv. hepatotropn\u00ED viry, predilek\u010Dn\u00EDm m\u00EDstem jejich replikace jsou j\u00E1tra a nejz\u00E1va\u017En\u011Bj\u0161\u00ED komplikac\u00ED chronick\u00E9 infekce t\u011Bmito viry je jatern\u00ED cirh\u00F3za. Oba viry se p\u0159en\u00E1\u0161\u00ED parenter\u00E1ln\u011B. Proti viru hepatitidy B je v sou\u010Dasn\u00E9 dob\u011B k dispozici vysoce \u00FA\u010Dinn\u00E1 a bezpe\u010Dn\u00E1 rekombinantn\u00ED vakc\u00EDna. Plo\u0161n\u00E9 o\u010Dkov\u00E1n\u00ED vedlo k v\u00FDrazn\u00E9mu sn\u00ED\u017Een\u00ED incidence nov\u00FDch p\u0159\u00EDpad\u016F HBV. U pacient\u016F, kte\u0159\u00ED trp\u00ED chronickou HBV infekc\u00ED, je nutno l\u00E9\u010Dbou zastavit replikaci viru. Prvn\u00ED mo\u017Enost\u00ED je dosa\u017Een\u00ED imunitn\u00ED kontroly replikace l\u00E9\u010Dbou peginterferonem alfa, druhou mo\u017Enost\u00ED je dlouhodob\u00E9 pod\u00E1v\u00E1n\u00ED syntetick\u00FDch antivirotik, prvn\u00ED volbou je dnes tenofovir nebo entekavir. Proti viru hepatitidy C nen\u00ED v sou\u010Dasn\u00E9 dob\u011B k dispozici \u00FA\u010Dinn\u00E1 vakcinace. P\u0159enosu infekce je nutno se br\u00E1nit dodr\u017Eov\u00E1n\u00EDm hygienick\u00FDch z\u00E1sad v rodin\u00E1ch i ve zdravotnick\u00FDch za\u0159\u00EDzen\u00EDch, vysoce d\u016Fle\u017Eit\u00E9 je prov\u00E1d\u011Bt screening v rizikov\u00FDch skupin\u00E1ch osob. Chronickou HCV infekci lze l\u00E9\u010Dbou eliminovat z organizmu, \u00FA\u010Dinn\u00E1 je pouze kombinace peginterferonu alfa s ribavirinem, eliminace viru se zat\u00EDm da\u0159\u00ED dos\u00E1hnout jen u \u010D\u00E1sti l\u00E9\u010Den\u00FDch pacient\u016F."@cs . "Vakcinologie" . "chronic viral hepatitis; treatment; prevention; vaccination"@en . "L\u00E9\u010Dba a prevence chronick\u00FDch virov\u00FDch hepatitid"@cs . . "L\u00E9\u010Dba a prevence chronick\u00FDch virov\u00FDch hepatitid"@cs . "L\u00E9\u010Dba a prevence chronick\u00FDch virov\u00FDch hepatitid" . "HBV and HCV belong to family of hepatotropic viruses and the liver is a predilective site of their replication. Liver cirrhosis is then the most serious consequence of chronic infection caused by these viruses. Both infections are parenterally transmitted. Nowadays, a highly effective and safe recombinant vaccine available against hepatitis B virus is available. Routine vaccination led to a decrease in the incidence of new HBV cases. It is essential to stop the viral replication in patients chronically infected with HBV. The first therapeutical option is to achieve an immnune control of viral replication by treatment with peginterferon alpha, the second option is a long-term therapy with synthetic antivirals, tenofovir or entecavir as the first treatment choice today. Up to now, no effective medical treatment is available for HCV infection. We can prevent the spread of infection by perfect adherence to hygiene measures in families and hospitals. The screening programs in high risk groups are also crucial. The chronic HCV infection can be eradicated from the organism by treatment, only combination of peginterferon and ribavirin is effective. Nevertheless, the virus eradication is achieved only in some treated patients."@en . . "1"^^ . "2" . . "\u0160perl, Jan" . "1"^^ . "N" . . . . . "Treatment and prevention of chronic viral hepatitis"@en .